Wockhardt shares defied market trends on January 13, surging by up to 4% in early trading. The stock opened at ₹1,375.05, touched a high of ₹1,441.95, and later traded 2.90% higher at ₹1,427 on the BSE by mid-morning. This performance came in the wake of the company’s announcement of a clinical breakthrough for its novel antibiotic, Zaynich (Zidebactam/Cefepime, WCK 5222). The groundbreaking drug, set to debut in India by the end of FY25 and globally in FY26, is anticipated to have no competition for at least 15 years. With the global antibiotic market estimated at $25 billion, Zaynich positions Wockhardt as a key player in addressing the pressing issue of drug-resistant infections. Wockhardt’s six antibacterial discovery programs, granted QIDP status by the USFDA, underscore its leadership in combating superbugs. The company derives 79% of its revenues from international markets, including the USA and Europe, bolstering its global presence. The stock has delivered stellar returns, gaining nearly 210% over the past year. Despite a flat performance in January so far, the stock logged gains of 23% in October, 16% in November, and 1% in December, showcasing resilience amid broader market challenges.